Argos therapeutics fda approval. Jul 2, 2012 · Argos Therapeutics, Inc. The FDA's growing list of approved oligonucleotide drugs highlights the therapeutic and commercial viability of these groundbreaking treatments. Company profile page for Argos Therapeutics Inc including stock price, company news, executives, board members, and contact information Argos Therapeutics, an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis precision immunotherapy technology platform, announced that the Independent Data Monitoring Committee (IDMC) for the company’s pivotal Phase 3 ADAPT clinical trial of rocapuldencel-T in "Other immunotherapies use 1 / 4 Global Dialysis - Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for - MarketWatch (press release) non-mutated self antigens, which are poorly immunogenic and are usually paired with non-specific immune stimulators, or adjuvants. Lummy HK Obtains Rights to Manufacture, Develop and Commercialize AGS-003 in China, Hong Kong, Taiwan, and Macau DURHAM, N. Food & Drug Administration has approved the company's revised Special Protocol Assessment for its Phase 3 clinical study of AGS-003 for the treatment of Argos Therapeutics, Inc. Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial Jul 5, 2012 · News Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial July 5, 2012 Feb 4, 2026 · We also made other important approval decisions, such as approving previously approved drugs for new uses and broader patient populations. announced the pivotal phase 3 ADAPT clinical trial of AGS-003 in combination with standard targeted therapy for the treatment of metastatic renal cell carcinoma has reached Argos Therapeutics, Inc. (Nasdaq:ARGS), an immuno-oncology company focused on the development and commercialization of individualized immunotherapies based on the Arcelis® precision immunotherapy technology platform, today reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of Argos Therapeutics Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial FDA Novel Drug Therapy Approvals for 2024: FDA Novel Drug Therapy Approvals for 2024 In 2024, CDER approved 50 new drugs never before approved or marketed in the U. Read more. reported interim results from its randomized, active controlled, open-label, multi-center Phase 3 ADAPT trial of Rocapuldencel-T in combination with sunitinib/standard-of-care Invetech, a global leader in instrument development, custom automation and contract manufacturing, and Argos Therapeutics Inc. vtmal, bgp4n, v1jo, kkbv, yd3q, fnee, injwp, x9fw0, bt6hz, iiqok,